Nicorette study
This article was originally published in The Tan Sheet
Executive Summary
Smokers who used the smoking cessation gum even though they "were not ready to quit" were more likely to decrease daily cigarette consumption by at least 50% after one year compared to the placebo arm (8.8% versus 1.5% respectively), according to data collected in a Pfizer-sponsored, 411 smoker study conducted by P. Wennike et al. Presented at the World Conference on Tobacco or Health in early August, the study also shows a larger percentage of smokers who chew Nicorette stopped smoking completely compared to those taking placebo (11.2% versus 3.9%, respectively). GlaxoSmithKline markets Nicorette in the U.S through a licensing agreement with Pfizer...
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.